Class 540/454 - Chalcogen in the hetero ring

Subclass of Class 540 - Organic compounds -- part of the class 532-570 series
Definition: Compounds wherein the hetero ring contains chalcogen (i.e.,
No. of patents: 98
Last issue date: 09/02/2008

«First «Previous1 2 3 Next»Last»

Number	Title	Issue Date
7420051	Synthetic process for the manufacture of an ecteinaschidin compound Processes are provided for preparing compounds with a fused ring structure of formula (XIV). Such products include ecteinascidins and have a spiroamine-1,4-bridge. The process involving forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18-protected hydroxyl, di-6,8...	09/02/2008
7410969	Antitumoral analogs of ET-743 Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or d...	08/12/2008
7381743	Macrocycles for the treatment of cancer The present invention relates to new macrocycles of the general formula (I) as well as their use for the treatment of cancer diseases ...	06/03/2008
7371858	Guanidinopyrimidinone compounds and phase change inks containing same Compounds of the formulae wherein, provided that at least one of R1, R2, and R3 is not a hydrogen atom, R1, R2, and R3 each, independently of the other, is h...	05/13/2008
7317122	Curable trans-1,2-cyclohexane bis(urea-urethane) compounds Curable trans-1,2-cyclohexane bis(urea-urethane) compounds of the formulae wherein R1 and R′1 each, independently of the other, are alkylene, arylene, arylalkylene, or alkylarylene groups,...	01/08/2008
7314949	Trans-1,2-cyclohexane bis(urea-urethane) compounds Disclosed are trans-1,2-cyclohexane bis(urea-urethane) compounds of the formulae wherein R1 and R′1 each, independently of the other, is an alkylene group, an arylene group, an arylalkylen...	01/01/2008
7247629	Antitumoral analogs of et-743 Antitumour compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the C-1 position a substituent selected from an optionally protected or ...	07/24/2007
7220300	Phase change inks containing bis(urea-urethane) compounds Disclosed is a phase change ink composition comprising a phase change ink carrier and a bis(urea-urethane) compound of the formula wherein R1 and R1′ each, independently of the other, is a...	05/22/2007
7153349	Phase change inks containing curable trans-1,2-cyclohexane bis(urea-urethane) compounds Phase change inks comprising a phase change ink carrier and one or more curable trans-1,2-cyclohexane bis[urea-urethane] compounds of the formulae wherein R1 and R′1 are alkylene, arylene,...	12/26/2006
7144450	Phase change inks containing trans-1,2-cyclohexane bis(urea-urethane) compounds Disclosed are phase change inks comprising a phase change ink carrier and a trans-1,2-cyclohexane bis(urea-urethane) compound of the formula or mixtures thereof, wherein R1 and R′1 each, i...	12/05/2006
7109341	Therapeutic amides The invention provides compounds of the formula: wherein A, X, Y, and Z are as defined in the specification. The compounds are effective anti-tumor agents. The invention also provides pharmaceutical compositions ...	09/19/2006
7097759	Carbonyl, thiocarbonyl or imine containing compounds as asphaltene dispersants in crude oil A method for dispersing asphaltenes in a petroleum product by adding to the petroleum product 0.001% to 20% of at least one compound having formula (V) wherein R14 is C15–C21 al...	08/29/2006
7087752	Alkylated urea and triaminotriazine compounds and phase change inks containing same Compounds of the formulae wherein Z is OR1, SR1, or NR1R2, Y is OR3, SR3, or NR3R4, at ...	08/08/2006
7026309	Fused bicyclic pyridine derivative as tachykinin receptor antagonist A fused bicyclic pyridine derivative represented by the following general formula (1), or a salt thereof: wherein the rings A and B are each a benzene ring, which may have 1 to 3 substituents (a...	04/11/2006
6962992	Crown ether derivatives The invention describes crown ether chelators, including crown ethers having the formula and aza-substituted and thia-substituted analogs thereof. These crown ethers are substituted by a dye moiety, a chemically reacti...	11/08/2005
6936447	Autoinducer molecule Autoinducer molecules, e.g., N-(3-oxododecanoyl)homoserine lactone, for Pseudomonas aeruginosa are described. The molecules regulate gene expression in the bacterium. Therapeutic compositions and therapeutic methods involving analogs and/or inhibitors of the ...	08/30/2005
6930102	16-halogen-epothilone derivatives, process for their production, and their pharmaceutical use A compund of formula I, an epothilone derivative, its method of preparation, and use as a pharmaceutical agent in treating malignant tumors ...	08/16/2005
6900176	Pest control agents/depsipeptides The present invention relates to the use of 24-membered cyclodepsipeptides of the formula (1) in which R1 and R2 are as defined in the description, for controlling animal pests in veteri...	05/31/2005
6852713	Lactam derivatives and methods of their use Lactam derivatives of the general formula are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed. ...	02/08/2005
6680311	Cryptophycin compounds The present invention provides cryptophycin compounds of Formula I ##STR1## that are useful in the treatment of neoplasms....	01/20/2004
6608027	Macrocyclic peptides active against the hepatitis C virus The present invention covers macrocyclic compounds of formula I active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. ##STR1## wherein W, R21, R22, R3, R4, D and A are as defi...	08/19/2003
6593360	8a- and 9a-15-membered lactams The invention relates to novel 15-membered 8a- and 9a-lactams from the class of 6-O-methyl-erythromycin A of general formula (I) ##STR1## their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, to intermediates...	07/15/2003
6545038	Heterocyclic metalloprotease inhibitors The invention provides compounds of formula ##STR1## as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof are useful as inhibitors of...	04/08/2003
6521609	Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes A method for treating menopausal hot flushes using CGRP antagonists and/or CGRP release inhibitors and the corresponding pharmaceutical compositions containing as active substance one or more CGRP antagonists and/or CGRP release inhibitors, and the prepar...	02/18/2003
6384026	Macrocyclic polyamine lactones and derivatives thereof and their use as arthropod repellents The present invention describes an isolated macrocycle having the formula: ##STR1## where d is an integer from 0 to about 100; A, B, and each D are the same or different and are selected from the group consisting of ##STR2## each R1 is the same...	05/07/2002
6329338	Derivatives of cyclodepsipeptide PF1022 substance Novel derivatives of PF1022 substance, which are cyclodepsipeptides represented by the general formula (I) shown below or their salts are useful as anthelmintic agent for prevention or treatment of parasitic infections. ##STR1##...	12/11/2001
6307044	Process for the preparation of macrocyclic metalloprotease inhibitors The present invention is directed to a process for the preparation of a compound of formula (X-a): ##STR1## or a pharmaceutically acceptable salt form thereof, wherein: R1 is selected from the group consisting of: C1-5 alkyl substituted w...	10/23/2001
6281352	Macrocyclic compounds as metalloprotease inhibitors This invention relates to macrocyclic molecules which inhibit metalloproteinases, including aggrecanase, and the production of tumor necrosis factor (TNF). In particular, the compounds are inhibitors of metalloproteinases involved in tissue degradation an...	08/28/2001
6265572	Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agents Compounds of the formula: ##STR1## are described which have activity as anti-inflammatory agents. Cyclic disulfide compounds are provided which inhibit of binding of cells to endothelium. Such compounds are useful for treating inflammatory diseases, ...	07/24/2001
6252064	Process to prepare pharmaceutical compounds This invention provides a process for preparing diastereomerically pure cryptophycin compounds....	06/26/2001
6150527	Synthetic multimerizing agents New compounds are disclosed for multimerizing immunophilins and proteins containing immunophilin or immunophilin-related domains. The compounds are of the formula M-L-Q where M is a synthetic ligand for an FKBP protein...	11/21/2000
6133456	Synthetic multimerizing agents New compounds are disclosed for multimerizing immunophilins and proteins containing immunophilin or immunophilin-related domains. The compounds are of the formula M1 --L--M2 where M1 and M2 are independently moieties...	10/17/2000
6124453	Macrolides A novel class of macrolides in which i) positions 2 to 6 inclusive of the macrocyclic ring are provided by a piperidazinyl carboxylic acid residue; and/or ii) positions 7 to 9 inclusive of the macrocyclic ring are provided by an aromatic ଱-amino acid res...	09/26/2000
6110965	Ketolides from the class of 15-membered lactams The present invention relates to the new 15-membered ketoazalides from the class of 6-O-methyl-8a-aza-8a-homo-and 6-O-methyl-9a-aza-9a-homoerythromycin A with the general formula (I) ##STR1## wherein A represents NH group and B at the same time repre...	08/29/2000
6025350	C-4" substituted macrolide antibiotics This invention relates to compounds of the formula ##STR1## and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are potent antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infec...	02/15/2000
6025488	Formulations and methods of reducing toxicity of antineoplastic agents This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineopl...	02/15/2000
6015807	Protein kinase C inhibitor This invention provides novel bis-indolylmaleimide macrocycle derivatives of the formula: and solvates thereof. The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals....	01/18/2000
5972237	Use of heterocyclic compounds as activators for inorganic peroxy compounds Heterocyclic compounds I R1 --X--L (I) where L is a cyclic carbamate residue, a lactonoxy residue or a lactam residue, X is an oxygen-containing group ##STR1## where A is a linker, and R1 is an ...	10/26/1999
5952320	Macrocyclic inhibitors of matrix metalloproteinases and TNF଱ secretion Macrocyclic compounds of formula ##STR1## are potent inhibitors of matrix metalloproteinase and are useful in the treatment of diseases in which matrix metalloproteinase play a role. Also disclosed are matrix metalloproteinase inhibiting compositions...	09/14/1999
5936084	Halo-substituted bisindolemaleimide protein kinase C inhibitors The present invention is directed to novel halo-substituted bis-indolemaleimide compounds of the formula: ##STR1## The invention further provides a method of preparing the disclosed compounds and the preparation of pharmaceutical formulation for use ...	08/10/1999

«First «Previous1 2 3 Next»Last»

PatentStorm

Did You Know...

PatentStorm News

Class 540/454 - Chalcogen in the hetero ring